Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Incheon
Clinical trial register · South Korea

Clinical Trials in Incheon, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Eli Lilly and Company15 Hoffmann-La Roche14 Novartis Pharmaceuticals13 Janssen Research & Development, LLC11
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Incheon

351 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840Ischemic Stroke, Transient Ischemic Attack
DrugZastaprazan
Asan Medical Center
Phase 3
984
Daejeon, Gwangju, Gyeonggi-do, Incheon, Jeju City, Jeonju, Seoul
2026-10-15
Not yet open
Daewoong Pharmaceutical Co. LTD.
Phase 3
384
Incheon
2026-10-15
Recruiting
Hoffmann-La Roche
Phase 3
400
Busan, Incheon, Jeollanam-do
2026-09-30
Not yet open
GL Pharm Tech Corporation
Phase 3
228
Incheon
2026-09
Not yet open
Emotion Regulation Program for Substance Use Disorders
NCT07698821Substance Use Disorder (SUD)
The Catholic University of Korea
Not applicable
20
Daegu, Incheon
2026-09
Not yet open
AI-Based Cardiac Analysis Using 12-Lead and 1-Lead ECG
NCT07844434Heart Failure, Atrial Fibrillation (AF), Electrocardiogram
Inha University Hospital
Observational
300
Incheon
2026-08-30
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seongbuk-Gu, Seoul
2026-08-24
Recruiting
AstraZeneca
Phase 3
1,500
Busan, Daegu, Daejeon, Incheon, Seoul, Suwon
2026-08-20
Not yet open
Craving Management Program for Substance Use Disorders
NCT07698808Substance Use Disorder (SUD)
The Catholic University of Korea
Not applicable
20
Daegu, Incheon
2026-08
Not yet open
Seoul National University Hospital
Not applicable
1,724
Ansan, Anyang, Busan, Changwon, Cheonan, Daegu, Gwangju, Incheon
2026-07-29
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
Incheon
2026-07-24
Recruiting
BELL Therapeutics Inc.
Not applicable
40
Incheon, Seongnam-si, Seoul
2026-07-20
Recruiting
AstraZeneca
Phase 3
1,200
Busan, Changwon-si, Daegu, Daejeon, Guri-si, Incheon, Seoul
2026-07-06
Recruiting
SK Bioscience Co., Ltd.
Phase 3
780
Daegu, Ansan, Hwaseong-si, Seongnam-si, Incheon, Seoul
2026-07-04
Recruiting
AstraZeneca
Phase 3
4,500
Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Jongno-gu, Seoul, Suwon
2026-06-29
Not yet open
First Step Program for Substance Use Disorders
NCT07658963Substance Use Disorder (SUD)
The Catholic University of Korea
Not applicable
20
Daegu, Incheon
2026-06-22
Not yet open
Development of Multidimensional Screening Tool for WMSDs
NCT07367646Work-Related Musculoskeletal Disorders, Musculoskeletal Diseases, Occupational Diseases
Sahmyook University
Observational
250
Incheon
2026-06-20
Recruiting
Eikon Therapeutics
Phase 2/3
750
Daegu, Incheon
2026-06-15
Recruiting
AstraZeneca
Phase 3
150
Cheonan-si, Daegu, Goyang-si, Hwasun-eup, Incheon, Seongbuk-Gu, Seongnam-si, Seoul
2026-06-15
Recruiting
Pfizer
Phase 3
954
Daejeon, Anyang-si, Yangsan, Incheon, Seoul
2026-06-10
Recruiting
Samsung Medical Center
Observational
396
Daegu, Daejeon, Seongnam-si, Yangsan, Incheon, Jeju City, Jeonju, Hwasun
2026-05-28
Recruiting
AbbVie
Phase 3
990
Busan, Incheon, Seongnam, Suwon, Hwasun-gun, Seoul
2026-05-22
Recruiting
Transition of Care in Pediatric Rare Endocrine Disorders
NCT07786142Endocrine Disorder, Rare Disorders
Seoul National University Hospital
Not applicable
150
Daegu, Daejeon, Gwangju, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2026-05-20
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Gangnam-gu, Incheon, Namdong-gu, Seoul
2026-05-20
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Daegu, Wŏnju, Bundang Gu, Suwon, Incheon, Seoul, Busan, Gwangju
2026-05-11
Not yet open
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
NCT07482865Cardiogenic Shock, Acute Myocardial Infarction of Inferior Wall, Congestive Heart Failure, Myocarditis
Samsung Medical Center
Not applicable
500
Changwon, Incheon, Seoul
2026-05-01
Recruiting
Remibrutinib Open Label Roll-over Post-trial Access Protocol
NCT07456891Indication of the Parent Protocol
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
648
Daegu, Hwaseong-si, Suwon, Dongjak Gu, Seoul, Gwangju, Incheon
2026-04-16
Recruiting
Eli Lilly and Company
Phase 2
60
Dongjak-gu, Incheon, Jeonju, Seoul
2026-04-14
Recruiting
Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus
NCT07378956Diabetic Retinopathy (DR), Diabete Mellitus, Fundus Photography
VUNO Inc.
Not applicable
340
Incheon
2026-04-07
Recruiting
Yuhan Corporation
Phase 2
150
Gyeonggi-do, Daegu, Seoul, Yangsan, Incheon
2026-03-26
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Daegu, Seongnam-si, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seoul
2026-03-16
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Ansan-si, Seongnam-si, Incheon
2026-03-10
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Cheongju-si, Gwangju, Incheon, Seoul, Wŏnju
2026-03-03
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Cheongju-si, Incheon, Seongnam-si, Seoul, Suwon
2026-02-17
Recruiting
Young-Joon Kang
Observational
150
Incheon
2026-01-20
Recruiting
Contineum Therapeutics
Phase 2
324
Seoul, Bucheon-si, Seongnam-si, Songpa-dong, Incheon
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
Incheon, Seoul, Wŏnju
2026-01-07
Recruiting
Pharmacopuncture for Aromatase Inhibitor Induced Arthralgia (AIA)
NCT07789717Breast Cancer, Aromatase Inhibitor, Aromatase Inhibitor Induced Arthralgia
Ilsan Cha hospital
Not applicable
30
Daejeon, Goyang-si, Incheon
2026-01-05
Not yet open
Inha University Hospital
Phase 4
1,898
Incheon, Ansan, Bucheon-si, Busan, Cheonan, Goyang, Goyang-si, Guri-si
2026-01-01
Recruiting
ROKIT Healthcare
Phase 4
104
Daegu, Bucheon-si, Guri-si, Gwangmyeong, Seongnam-si, Goyang, Incheon, Jeonju
2025-12-29
Recruiting
Eli Lilly and Company
Phase 3
800
Cheonan-si, Deagu, Gangnam-gu, Gyeongsan-si, Incheon, Seoul
2025-12-22
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Suwon, Hwasun, Incheon, Seoul
2025-12-17
Recruiting
ALX Oncology Inc.
Phase 2
120
Incheon, Seoul
2025-12-10
Recruiting
Bristol-Myers Squibb
Phase 3
650
Incheon, Seoul, Deagu
2025-12-02
Recruiting
Gachon University Gil Medical Center
Phase 4
64
Busan, Chungju, Daegu, Daejeon, Gwangju, Incheon, Seoul, Wŏnju
2025-11-24
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ansan-si, Cheonan, Gyeonggi-do, Incheon, Seoul
2025-11-24
Recruiting
Deepsonbio
Not applicable
138
Cheonan, Hwaseong-si, Incheon, Seongnam-si, Suwon, Seoul
2025-11-20
Recruiting
AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM
NCT07347691Embolic Stroke of Undetermined Source
Inha University Hospital
Observational
92
Ansan, Incheon, Jeju City, Seoul, Suwon
2025-11-19
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Busan, Gwangju, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2025-11-12
Recruiting
AI-Assisted Chemotherapy Side Effect Management
NCT07198581Breast Cancer, Colorectal Cancer
Incheon St.Mary's Hospital
Not applicable
174
Incheon
2025-11-12
Active, closed
Pfizer
Phase 2
42
Incheon, Seoul
2025-11-10
Recruiting
AstraZeneca
Phase 3
400
Goyang-si, Incheon, Seoul, Suwon
2025-10-31
Recruiting
GlaxoSmithKline
Phase 2
363
Busan, Incheon, Jeonju, Seoul
2025-10-30
Recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Incheon, Busan, Seoul
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju
2025-10-15
Recruiting
AstraZeneca
Observational
130
Busan, Daejeon, Goyang-si, Guri-si, Incheon, Seongnam-si, Seoul, Suwon
2025-10-15
Recruiting
Pfizer
Phase 2/3
982
Incheon, Seongnam, Seongnam-si, Seoul, Daegu, Busan
2025-10-03
Recruiting
Samsung Medical Center
Not applicable
3,500
Bucheon-si, Daegu, Gwangju, Gwangmyeong, Ilsan, Incheon, Jeonju, Jinju
2025-10-02
Recruiting
Traws Pharma, Inc.
Phase 2
90
Gwangju, Seoul, Wŏnju, Incheon
2025-09-16
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
358
Ansan, Suwon, Busan, Gyeonggi-do, Incheon, Seoul
2025-08-29
Recruiting
Seoul National University Bundang Hospital
Phase 2
130
Busan, Daegu, Gangneung, Seongnam-si, Incheon, Hwasun, Cheongju-si, Seoul
2025-08-27
Recruiting
MapLight Therapeutics
Phase 2
300
Daegu, Incheon
2025-08-15
Active, closed
Taejoon Pharmaceutical Co., Ltd.
Phase 3
351
Incheon
2025-08-11
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Seoul, Incheon
2025-08-07
Recruiting
NeuroBiogen Co., Ltd
Phase 2
114
Gwangju, Guri-si, Suwon, Incheon, Seoul
2025-08-06
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
484
Ansan, Bucheon-si, Suwon, Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2025-07-28
Recruiting
Amgen
Phase 3
12,800
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Gyeonggi-do, Seoul, Ulsan, Wonju-si, Gangwon-do
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Goyang, Incheon, Seongnam-si, Seoul, Suwon, Ulsan
2025-07-24
Recruiting
Pusan National University Yangsan Hospital
Phase 2
186
Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju, Seongnam, Seoul
2025-07-23
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Ansan-si, Bucheon-si, Busan, Daejeon, Daejoen, Gwangju, Incheon, Seongnam
2025-07-22
Recruiting
Daiichi Sankyo
Phase 2
130
Busan, Daegu, Goyang-si, Incheon, Jeonju, Seongnam, Seoul, Suwon
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Cheongju-si, Goyang-si, Incheon, Seoul
2025-07-17
Recruiting
Bristol-Myers Squibb
Phase 3
426
Incheon, Seoul, Deagu
2025-07-16
Recruiting
Asan Medical Center
Phase 4
2,340
Seoul, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon
2025-07-10
Recruiting
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
NCT07405931Early Gastric Cancer, Advanced Gastric Cancer, Early Lung Cancer, Advanced Lung Cancer
Ulsan University Hospital
Not applicable
414
Busan, Goyang, Incheon, Jinju, Ulsan
2025-07-09
Recruiting
Incheon St.Mary's Hospital
Phase 4
160
Ansan, Busan, Chilgok, Chuncheon, Gwangju, Incheon, Seoul, Yangsan
2025-07-07
Recruiting
Personalized Health Coaching for Patients With HF
NCT07111585Heart Failure, Frailty, Health Coaching, Telenursing
Gachon University Gil Medical Center
Not applicable
80
Incheon
2025-07-03
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-07-02
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Incheon, Seoul
2025-07-02
Active, closed
Upstream Bio Inc.
Phase 2
666
Wŏnju, Seongnam-si, Incheon, Seoul
2025-07-02
Recruiting
NGM Biopharmaceuticals, Inc
Phase 2
136
Goyang, Incheon, Seoul, Suwon
2025-06-25
Recruiting
GlaxoSmithKline
Phase 3
961
Daegu, Incheon, Jeonju, Seoul
2025-06-23
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Anyang, Chungju, Daegu, Dong-gu Ulsan, Incheon, Seoul, Wŏnju
2025-06-09
Recruiting
Regeneron Pharmaceuticals
Phase 2
297
Gyeonggi-do, Seongnam-si, Incheon, Daegu, Seoul
2025-05-28
Recruiting
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
NCT06962098Diabetic Kidney Disease (DKD)
Aptabio Therapeutics, Inc.
Phase 2
186
Ansan-si, Busan, Cheonan, Daegu, Goyang-si, Guri-si, Gwangmyeong, Incheon
2025-05-26
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Goyang-si, Seongnam-si, Suwon, Hwasungun, Cheongju-si, Seocho-gu, Daegu, Incheon
2025-05-22
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Busan, Gwangju, Incheon, Seongnam, Seoul, Wŏnju
2025-05-20
Recruiting
Samsung Medical Center
Not applicable
1,200
Ansan, Daegu, Gangneung, Goyang, Gwangju, Gwangmyeong, Incheon, Jeonju
2025-04-07
Recruiting
Daiichi Sankyo
Phase 3
510
Daegu, Goyang-si, Hwasun-gun, Incheon, Seongnam-si, Seoul
2025-03-27
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
NCT06785818B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals
Observational
500
Bundang Gu, Seongnam-si, Gyeonggi-do, Incheon, Seoul, Busan, Jeollanam, Ulsan
2025-03-12
Active, closed
Amgen
Phase 3
3,853
Ansan-si, Gyeonggi-do, Anyang-si, Gyeonggi-do, Bucheon, Gyeonggi-do, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon
2025-03-12
Recruiting
BioNTech SE
Phase 2
60
Jinju, Cheongju-si, Incheon, Seoul
2025-03-03
Recruiting
Incyte Corporation
Phase 3
600
Ansan-si, Busan, Incheon, Seoul, Yangsan
2025-02-28
Recruiting
Daiichi Sankyo
Phase 3
726
Cheongju-si, Daegu, Goyang-si, Hwasun-gun, Incheon, Jeonju, Seongnam, Seongnam-si
2025-02-27
Recruiting
Seong Hye Choi, MD
Not applicable
40
Incheon, Seoul, Suwon
2025-02-26
Recruiting
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
NCT06889818Mild Cognitive Impairment, Dementia, Subjective Cognitive Decline (SCD), Alzheimer Disease
Ewha Womans University Mokdong Hospital
Observational
4,000
Incheon, Seoul
2025-02-24
Active, closed
Sanofi
Phase 3
231
Cheonan-Si, Seongnam-si, Incheon, Seoul
2025-02-12
Recruiting
BioNTech SE
Phase 3
621
Seoul, Goyang-si, Suwon, Jinju, Incheon, Cheongju-si
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
2025-01-07
Active, closed
Pfizer
Phase 3
1,035
Seongnam-si, Incheon, Goyang-si, Seongnam, Gangnam-gu, Seoul
2025-01-06
Active, closed
mAbxience Research S.L.
Phase 3
726
Busan, Gyeonggi-do, Incheon, Seoul
2024-12-30
Active, closed
Inha University Hospital
Not applicable
400
Incheon
2024-12-25
Recruiting
Duk-Woo Park, MD
Phase 4
1,040
Bucheon-si, Changwon, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon
2024-12-18
Recruiting
S-Alpha Therapeutics, Inc.
Observational
40
Seoul, Hwaseong-si, Gwangmyeong, Incheon
2024-12-16
Recruiting
UCB Biopharma SRL
Phase 3
450
Busan, Incheon, Seoul, Suwon
2024-11-21
Active, closed
Daiichi Sankyo
Phase 3
700
Busan, Daegu, Hwasun-gun, Incheon, Jeonju, Seongnam-si, Seoul, Suwon
2024-11-19
Recruiting
Seoul St. Mary's Hospital
Not applicable
800
Incheon, Seoul, Suwon, Uijeongbu-si
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon
2024-11-18
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Bucheon-si, Busan, Incheon, Seoul, Wŏnju
2024-11-12
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Incheon, Dongjak, Seoul
2024-10-29
Active, closed
Eli Lilly and Company
Phase 3
1,400
Busan, Cheongju-si, Gangnam-gu, Gangseo-gu, Gwangju, Incheon, Jeju City, Namdong-gu
2024-10-24
Recruiting
BioMarin Pharmaceutical
Phase 2
100
Seongnam-si, Incheon, Sejong
2024-10-21
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Bucheon-si, Busan, Deagu, Incheon, Seoul, Wŏnju
2024-10-14
Active, closed
Incyte Corporation
Phase 3
349
Ansan-si, Bucheon-si, Busan, Incheon, Jeonju, Seoul
2024-10-10
Recruiting
Rznomics, Inc.
Phase 1/2
43
Incheon, Seongnam-si, Seoul
2024-10-08
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Cheongju-si, Seongnam-si, Incheon, Seoul, Busan, Daegu, Gyeonggi-do, Ulsan
2024-09-27
Active, closed
Hoffmann-La Roche
Phase 3
338
Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2024-09-23
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
DrugsABP 234·Pembrolizumab
Amgen
Phase 3
163
Suwon, Jeonju, Cheongju-si, Busan, Incheon, Seoul
2024-09-12
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Daegu, Incheon, Goyang-si, Seoul
2024-09-04
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Incheon, Namdong-gu, Seoul
2024-08-22
Recruiting
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
NCT06184009Pediatric Acute Lymphoblastic Leukemia
Jae Wook Lee
Phase 2
370
Seoul, Incheon, Suwon, Yangsan
2024-08-10
Active, closed
BioNTech SE
Phase 2
110
Cheongju-si, Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2024-08-05
Active, closed
GlaxoSmithKline
Phase 3
10,212
Seoul, Ansan, Bucheon-si Kyunggi-do 14584, Daegu, Incheon, Jeonju, Kangwon-do, Suwon Gyeonggi-do
2024-08-01
Recruiting
Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study
NCT06505577Mastectomy, Breast Neoplasm Malignant Primary
Incheon St.Mary's Hospital
Observational
600
Incheon
2024-08-01
Recruiting
AstraZeneca
Phase 2
80
Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon
2024-07-16
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Gyeonggi-do, Suwon, Hwasun, Incheon, Seoul, Ulsan
2024-07-16
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Bucheon-si, Busan, Cheongju-si, Daejeon, Deagu, Gwangju, Incheon, Seongnam
2024-06-17
Recruiting
Real-World Treatment Study of Koselugo (Selumetinib)
NCT06360406Neurofibromatosis 1, Neurofibroma, Plexiform
AstraZeneca
Observational
200
Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju
2024-06-15
Recruiting
Duk-Woo Park, MD
Not applicable
1,500
Bucheon-si, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon, Pusan
2024-06-14
Active, closed
GlaxoSmithKline
Phase 3
88
Daegu, Incheon, Seoul
2024-06-10
Recruiting
Inha University Hospital
Observational
50
Incheon
2024-06-03
Recruiting
Lomond Therapeutics Holdings, Inc.
Phase 1
150
Incheon, Seoul
2024-05-29
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Bucheon-si, Busan, Daegu, Incheon, Seoul
2024-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Bupyeong-gu, Hwasun, Suwon, Yangsan, Daegu, Junggu, Incheon, Seoul
2024-05-24
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
DrugsTucatinib·Disitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Seongnam-si, Busan, Goyang-si, Seoul, Cheongju-si, Incheon, Suwon
2024-05-20
Active, closed
Hoffmann-La Roche
Phase 2
256
Incheon
2024-05-02
Active, closed
Eli Lilly and Company
Phase 3
450
Busan, Incheon, Seongnam-si, Seoul
2024-04-26
By invitation
ACADIA Pharmaceuticals Inc.
Phase 3
752
Seoul, Incheon
2024-04-23
Recruiting
AstraZeneca
Phase 3
675
Changwon, Incheon, Seongnam-si, Seoul, Suwon
2024-04-11
Recruiting
OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
NCT06227754ST Elevation Myocardial Infarction, Myocardial Infarction
Chonnam National University Hospital
Not applicable
1,500
Daegu, Gwangju, Iksan, Incheon, Jeju City, Jeonju, Jinju, Seoul
2024-03-25
Active, closed
Bristol-Myers Squibb
Phase 2
310
Songpa-gu, Gwangjingu, Incheon, Junggu
2024-03-20
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2024-03-13
Recruiting
Korean Society of Hematology
Phase 2
69
Incheon
2024-03-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Bundang Gu, Gyeonggi-do, Seoul, Incheon, Seongnam Gyeonggi
2024-02-28
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
Incheon, Seoul
2024-02-26
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Cheongju Chungbuk, Goyang-si Gyeonggi-do, Incheon, Jinju, Seongnam-si, Gyeonggi-do, Seoul
2024-02-20
Active, closed
Janssen Research & Development, LLC
Phase 2
305
Cheongju-si, Incheon, Seoul
2024-02-16
Active, closed
Regeneron Pharmaceuticals
Phase 3
216
Gyeonggi-do, Suwon, Yangsan, Jeonju, Incheon, Busan, Daegu, Seoul
2024-02-15
Active, closed
Boehringer Ingelheim
Phase 3
428
Cheongiu, Goyang, Incheon, Seoul, Suwon
2024-02-09
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
180
Daegu, Seongnam, Seongnam-si, Incheon, Seoul
2024-01-31
Recruiting
Genexine, Inc.
Phase 3
429
Ansan, Incheon, Seoul
2024-01-25
Active, closed
DualityBio Inc.
Phase 3
541
Busan, Wŏnju, Seongnam-si, Seoul, Suwon, Incheon, Cheonan, Ulsan
2024-01-18
Recruiting
Colorado Prevention Center
Phase 3
5,200
Gwangju, Wŏnju, Seoul, Bucheon-si, Incheon, Daejeon, Cheongju-si, Busan
2024-01-17
Active, closed
Samsung Bioepis Co., Ltd.
Phase 1
163
Ansan, Busan, Daegu, Hwasun, Incheon, Jinju, Seongnam, Seoul
2024-01-16
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
150
Daegu, Busan, Seongam, Seongnam-si, Incheon, Seoul
2024-01-09
Recruiting
Regeneron Pharmaceuticals
Phase 3
580
Suwon, Jeonju, Incheon, Busan, Daegu, Seoul, Ulsan
2023-12-28
Active, closed
TransThera Sciences (Nanjing), Inc.
Phase 3
200
Seongnam-si, Jinju, Hwasun, Busan, Daegu, Incheon, Seoul
2023-12-20
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Seongnam-si, Suwon, Jinju, Incheon, Seoul
2023-12-18
Recruiting
AstraZeneca
Phase 3
1,145
Goyang-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-12-14
Recruiting
Regeneron Pharmaceuticals
Phase 3
904
Suwon, Incheon, Busan, Daegu, Seoul
2023-12-13
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Haeundae, Gwangju, Seoul, Gyeonggi-do, Incheon, Jeonju
2023-12-11
Recruiting
Eikon Therapeutics
Phase 1/2
156
Seongnam-si, Incheon, Seoul
2023-12-11
Recruiting
AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
NCT07859020Tachycardia, Paroxysmal Supraventricular Tachycardia, Wolff-Parkinson-White Syndrome, Premature Ventricular Contractions
Inha University Hospital
Observational
10,000
Incheon
2023-12-01
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2023-12-01
Active, closed
Cellid Co., Ltd.
Phase 3
4,000
Busan, Daegu, Daejeon, Gwangju, Gyeonggi-do, Incheon, Seoul
2023-11-27
Recruiting
Amgen
Phase 3
750
Busan, Goyang-si Gyeonggi-do, Incheon, Seoul, Yangsan-si, Gyeongsangnam-do
2023-11-16
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Cheongju-si, Incheon, Seoul
2023-11-14
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673Alzheimer's Disease Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2/3
1,074
Incheon, Seoul
2023-11-14
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2023-11-10
Active, closed
GlaxoSmithKline
Phase 4
50
Incheon, Junggu, Kyungki-do, Seongnam-si Gyeonggi-do, Seoul
2023-11-10
Recruiting
Astellas Pharma Korea, Inc.
Observational
202
Goyang-si, Suwon, Jeollanam-do, Jeonju, Busan, Daegu, Daejeon, Incheon
2023-11-01
Recruiting
United Therapeutics
Phase 3
698
Incheon, Seongnam-si, Seoul
2023-10-30
Active, closed
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
NCT06027307Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
DrugEnavogliflozin
Asan Medical Center
Phase 3
541
Incheon, Seoul
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Cheongju-si, Incheon, Jinju, Seoul, Suwon
2023-10-24
Active, closed
Yuhan Corporation
Phase 4
198
Wŏnju, Seoul, Busan, Daejeon, Gwangju, Gyeonggi-do, Incheon
2023-10-18
Recruiting
AbbVie
Phase 3
1,500
Busan, Daegu, Daejeon, Seongnam-si, Incheon, Jeonju, Seoul
2023-10-11
Recruiting
S-Alpha Therapeutics, Inc.
Not applicable
110
Incheon
2023-09-27
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Goyang-si, Seongnam-si, Suwon, Hwasun-gun, Iksan-si, Busan, Incheon, Seoul
2023-09-22
Recruiting
Regeneron Pharmaceuticals
Phase 3
410
Incheon, Jeonju, Hwasun, Busan, Seoul
2023-09-18
Recruiting
Ipsen
Phase 3
276
Bucheon-si, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Junggu
2023-08-31
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Buk-gu, Seongnam-si, Incheon, Seoul, Busan
2023-08-28
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
160
Seongnam-si, Suwon, Incheon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-08-08
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Goyang-si, Suwon, Jinju, Incheon, Hwasun-gun, Seoul, Soeul
2023-07-31
Recruiting
Vividion Therapeutics, Inc.
Phase 1
290
Goyang, Incheon, Seongnam, Seoul, Suwon
2023-07-28
Recruiting
A Study of TXN10128 in Subjects With Solid Tumors
NCT05978492Locally Advanced (Unresectable) or Metastatic Solid Tumors
DrugsIrinotecan·Paclitaxel
Txinno Bioscience Inc.
Phase 1
96
Seongnam-si, Cheonju, Seoul, Incheon
2023-07-27
Recruiting
Boryung Pharmaceutical Co., Ltd
Observational
9,000
Incheon
2023-07-26
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Buk-gu, Ansan-si, Seongnam-si, Yongin-si, Incheon, Seoul, Yeongdeungpo-gu, Gangwon-do
2023-07-11
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Incheon, Suwon, Cheongju-si, Daejeon, Seoul, Ulsan
2023-06-30
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Bucheon-si, Daegu, Gyeonggi-do, Incheon, Jeollabuk-do, Seoul, Wŏnju
2023-06-28
Active, closed
The AIUR Trial: Surgical Gloves to Prevent Peripheral Neuropathy
NCT05771974Chemotherapy-induced Peripheral Neuropathy
Young-Joon Kang
Not applicable
104
Incheon
2023-06-13
Recruiting
Novartis Pharmaceuticals
Observational
44
Daegu, Suwon, Incheon, Seoul, Busan, Daejeon, Jeollanam
2023-06-12
Recruiting
Hoffmann-La Roche
Phase 3
420
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2023-06-07
Active, closed
Amgen
Phase 3
509
Cheongju Chungbuk, Goyang-si Gyeonggi-do, Incheon, Jinju, Seongnam-si, Gyeonggi-do, Seoul, Ulsan
2023-05-31
Active, closed
Janssen Research & Development, LLC
Phase 2
68
Cheongju-si, Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2023-05-18
Recruiting
Takeda
Phase 3
240
Daegu, Incheon, Seoul
2023-05-16
Recruiting
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NCT06088121Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases
Advanced Technology & Communications
Not applicable
180
Incheon, Gwangmyeong, Jeonju, Gwangju, Daegu, Gyeonggi-do, Daejeon, Seoul
2023-05-15
Active, closed
Gilead Sciences
Phase 3
654
Gangnam-Gu, Goyang-si Gyeonggi-do, Gyeongsangbuk-do, Incheon, Seongnam, Seoul
2023-05-08
Active, closed
Hoffmann-La Roche
Phase 2
204
Gyeonggi-do, Incheon, Seoul
2023-04-13
Active, closed
Sanofi
Phase 2
999
Ansan-si, Bucheon-si, Yangsan, Incheon, Seoul
2023-04-03
Active, closed
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan
Enliven Therapeutics
Phase 1
198
Suwon, Incheon, Seoul
2023-03-20
Recruiting
Regeneron Pharmaceuticals
Phase 3
202
Suwon, Incheon, Busan, Seoul
2023-03-07
Active, closed
AstraZeneca
Phase 2
188
Busan, Cheongju-si, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2023-03-06
Recruiting
AI-Powered Electrocardiography for Diagnosis and Prognostic Prediction in Cardiovascular Disease (AI-CVD): Multicenter Retrospective Study
NCT07856472Cardiovascular Diseases, Coronary Artery Disease, Heart Failure, Atrial Fibrillation (AF)
Inha University Hospital
Observational
10,000
Incheon
2023-03-01
Recruiting
Eli Lilly and Company
Phase 3
595
Busan, Cheonan-si, Daejeon, Incheon, Jeonju, Junggu, Seongnam-si, Seoul
2023-02-27
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Anyang-si, Busan, Daegu, Daejeon, Goyang-si, Gwangju, Incheon, Jeju Special
2023-02-15
Active, closed
Areteia Therapeutics
Phase 3
600
Anyang-si, Bucheon-si, Busan, Gwangju, Incheon, Jeonju, Seoul, Suwon
2023-01-30
Recruiting
Abion Inc
Phase 2
178
Goyang-si, Suwon, Dongjak, Seoul, Sinchon-dong, Cheongju-si, Incheon, Jinju
2023-01-17
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Wŏnju, Seongnam-si, Suwon, Daegu, Ansan-si, Busan, Daejeon, Incheon
2023-01-16
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Incheon, Seoul, Yongsan-Ku Seoul
2023-01-02
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Seongnam-si, Gwangju, Seoul, Chuncheon, Incheon, Cheonan, Daegu, Guri-si
2022-12-23
Active, closed
Amgen
Phase 3
7,297
Busan, Gwangju, Incheon, Seongnam-si, Gyeonggi-do, Seoul, Ulsan, Wonju-si, Gangwon-do
2022-12-14
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Cheongju-si, Goyang-si, Incheon, Jeollanam-do, Seongnam, Seoul
2022-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Daegu, Hwaseong-si, Suwon, Incheon, Seoul, Gwangju
2022-12-09
Recruiting
NRG Oncology
Phase 3
428
Seoul, Incheon
2022-12-07
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Busan, Incheon, Jeonju, Seongnam, Seoul, Wŏnju
2022-12-05
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bucheon-si, Seongnam-si, Yangsan, Daegu, Daejeon, Incheon, Seongnam-si, Gyeonggi-do, Seoul
2022-11-01
Recruiting
Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction
NCT05490433Breast Cancer Classified as TNM Stage 0-IIIa
Yonsei University
Not applicable
790
Changwon, Daegu, Goyang-si, Incheon, Pusan, Sejong, Seoul, Yongin-si
2022-10-26
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Busan, Daegu, Goyang-si, Hwasun, Incheon, Seoul
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Incheon, Seoul
2022-10-24
Active, closed
GlaxoSmithKline
Phase 2
351
Incheon, Seoul, Suwon Gyeonggi-do
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Busan, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seoul
2022-10-13
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Active, closed
Eli Lilly and Company
Phase 3
8,000
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Gyeongsan-si, Hwasun-gun, Incheon
2022-10-04
By invitation
Comparison Study Between Suction Aspiration and Combination Technique in Acute Cerebral Infarction
NCT06254755Acute Cerebral Ischemia Requiring for Mechanical Thrombectomy
Inje University Haeundae Paik Hospital
Not applicable
1,132
Goyang-si, Seongnam-si, Changwon, Bucheon-si, Daegu, Daejeon, Incheon, Pohang
2022-10-01
Active, closed
Seoul National University Bundang Hospital
Observational
1,000
Bucheon-si, Chungju, Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju
2022-09-28
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Incheon, Seoul, Suwon
2022-09-16
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
DrugTreprostinil
United Therapeutics
Phase 3
1,850
Seongnam-si, Incheon, Seoul
2022-09-06
Recruiting
Yuhan Corporation
Phase 1/2
147
Seongnam-si, Suwon, Jinju, Cheongju-si, Incheon, Seoul, Ulsan
2022-08-26
Active, closed
GlaxoSmithKline
Phase 3
3,038
Ansan, Bucheon-si, Incheon, Kangwon-do, Seoul
2022-08-10
Active, closed
Regeneron Pharmaceuticals
Phase 3
202
Suwon, Incheon, Busan, Seoul
2022-08-01
Active, closed
Drug-Coated Balloon in Patients With High Bleeding Risk
NCT05221931Coronary Artery Disease
Samsung Medical Center
Not applicable
1,359
Ansan, Cheongju-si, Daegu, Gangneung, Gwangju, Gwangmyeong, Incheon, Jinju
2022-07-29
Active, closed
PureTech
Phase 2
240
Bucheon-si, Goyang-si, Busan, Daegu, Gwangju, Gyeonggi-do, Incheon, Seoul
2022-07-22
Active, closed
Incyte Corporation
Phase 1/2
53
Suwon, Busan, Daegu, Incheon, Jeonju, Seoul, Ulsan
2022-07-19
Recruiting
Actelion
Phase 3
280
Daejeon, Incheon, Seoul
2022-05-04
Recruiting
ORIC Pharmaceuticals
Phase 1/2
350
Cheongju-si, Goyang-si, Gyeonggi-do, Incheon, Seongnam-si, Seoul
2022-03-10
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Wŏnju, Goyang-si, Seongnam-si, Suwon, Cheongju-si, Seoul, Busan, Incheon
2022-03-07
Active, closed
AstraZeneca
Phase 3
791
Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2022-02-18
Recruiting
Takeda
Phase 3
120
Daegu, Incheon, Seongnam, Seoul
2022-02-10
Recruiting
Takeda
Phase 2
135
Incheon, Seoul
2021-12-16
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Anyang-si, Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2021-12-02
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Daegu, Wŏnju, Bundang Gu, Jinju, Yangsan, Incheon, Seoul, Cheongju-si
2021-11-23
Active, closed
AstraZeneca
Phase 3
148
Daejeon, Goyang-si, Incheon, Seoul
2021-10-28
Active, closed
Boehringer Ingelheim
Phase 1
151
Incheon, Seongnam, Seoul
2021-10-18
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Daegu, Incheon, Jeollanam-do, Seoul
2021-10-14
Recruiting
Pfizer
Phase 3
893
Seongnam-si, Hwasun-gun, Busan, Seoul, Daegu, Incheon
2021-10-04
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Cheonan-si, Cheongju-si, Gangwon-do, Gyeonggi-do, Incheon, Namdong-Gu, Seongbuk-Gu, Seongnam
2021-08-27
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gangseo-gu, Goyang-si, Incheon
2021-08-14
Active, closed
AstraZeneca
Phase 3
712
Busan, Goyang-si, Incheon, Seongnam-si, Seoul
2021-08-05
By invitation
UCB Biopharma SRL
Phase 3
760
Incheon, Seoul
2021-07-27
Active, closed
Hoffmann-La Roche
Phase 3
451
Busan, Daegu, Incheon, Seongnam-si, Seoul
2021-07-14
Active, closed
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634Head and Neck Squamous Cell Carcinoma, Oral Mucositis
DrugCCRT
MitoImmune Therapeutics
Phase 2
60
Suwon, Jeonju, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Seoul
2021-06-21
Active, closed
Biogen
Phase 3
548
Suwon, Busan, Incheon, Seoul
2021-05-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Incheon, Seoul
2021-05-12
Active, closed
Incyte Corporation
Phase 3
899
Busan, Daegu, Goyang-si, Incheon, Jeonju, Jinju, Seoul, Yangsan
2021-05-11
Active, closed
ALX Oncology Inc.
Phase 2
172
Cheongju-si, Daegu, Incheon, Seongnam, Seongnam-si, Seoul
2021-05-10
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
170
Seoul, Incheon
2021-05-07
Recruiting
Ipsen
Phase 1/2
240
Goyang-si, Incheon, Seongnam-si, Seoul
2021-04-29
Active, closed
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsBispecific·Tagrisso·Osimertinib
Merus B.V.
Phase 1/2
194
Incheon, Seoul, Suwon, Gyeonggi-do
2021-04-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Jeollanam-do, Gyeonggi-do, Songpagu, Daegu, Incheon, Seoul
2021-04-21
Active, closed
Incyte Corporation
Phase 3
654
Busan, Daegu, Daejeon, Incheon, Jeonju, Seoul
2021-04-15
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Jinju, Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Ulsan
2021-04-09
Active, closed
ALX Oncology Inc.
Phase 2
189
Cheongju-si, Daegu, Daejeon, Gyeonggi-do, Incheon, Seongnam, Seoul, Suwon
2021-04-02
Active, closed
Hoffmann-La Roche
Phase 1/2
241
Incheon, Seoul
2021-03-15
Active, closed
Novartis Pharmaceuticals
Phase 3
345
Wŏnju, Incheon, Seoul, Gwangju
2021-03-01
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Goyang, Incheon, Seoul
2021-02-23
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Busan, Cheongju-si, Daegu, Hwasun-gun, Incheon, Junggu, Seongnam-si, Seoul
2021-02-23
Active, closed
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
DrugsDomvanalimab·Zimberelimab·Pemetrexed·Paclitaxel
Arcus Biosciences, Inc.
Phase 2
169
Daegu, Incheon, Jinju, Seoul, Suwon
2021-02-08
Active, closed
Pfizer
Phase 3
841
Goyang-si, Busan, Daegu, Incheon, Seoul
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Daegu, Hwasun-gun, Incheon, Seoul, Yangsan
2020-12-16
Active, closed
Daiichi Sankyo
Phase 3
1,600
Daegu, Gyeonggi-do, Incheon, Irwon-dong, Seoul, Songpa-gu, Yongsan
2020-12-04
Active, closed
Kyungpook National University Hospital
Phase 2
364
Daegu, Daejeon, Gwangju, Incheon, Jeonju, Seoul
2020-10-23
Active, closed
Bayer
Phase 3
402
Gwangju, Chungcheongbuk-do, Daegu, Incheon, Seoul
2020-10-20
Active, closed
Hoffmann-La Roche
Phase 3
992
Cheongju-si, Daegu, Gyeonggi-do, Incheon, Seoul, Ulsan
2020-10-09
Recruiting
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
NCT04499859Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
DrugsEzetimibe·Rosuvastatin
Kiyuk Chang, MD,PhD
Phase 4
3,548
Bucheon-si, Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul
2020-10-01
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
59
Daegu, Gyeonggi-do, Incheon, Seoul
2020-09-10
Active, closed
AbbVie
Phase 3
330
Busan, Incheon, Seoul
2020-08-31
Active, closed
PharmaEssentia
Phase 3
174
Daegu, Incheon, Seoul
2020-08-25
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
239
Goyang-si, Suwon, Jeonju, Busan, Daegu, Incheon, Seoul
2020-08-20
Active, closed
AstraZeneca
Phase 3
866
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2020-07-24
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
Incheon, Seoul
2020-07-01
Active, closed
Epizyme, Inc.
Phase 3
599
Seoul, Busan, Incheon, Suwon
2020-06-11
Active, closed
GlaxoSmithKline
Phase 1/2
106
Incheon, Seoul, Ulsan
2020-06-08
Active, closed
AstraZeneca
Phase 2
240
Goyang-si, Incheon
2020-04-22
Active, closed
AstraZeneca
Phase 3
818
Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon
2020-04-16
Active, closed
GlaxoSmithKline
Phase 3
325
Gyeonggi-do, Hwasun, Incheon, Seongnam-si Gyeonggi-do, Seoul
2020-04-02
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Seongnam-si, Busan, Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2020-02-28
Active, closed
Eli Lilly and Company
Phase 3
261
Goyang-si, Seongnam-si, Incheon, Seoul, Jinju, Dongjak-gu, Daejeon
2020-02-17
Recruiting
National Cancer Center, Korea
Phase 3
1,700
Busan, Chuncheon, Daegu, Goyang, Gwangju, Incheon, Seoul
2020-02-15
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
95
Gyeonggi-do, Seongnam-si, Suwon, Pusan, Hwasun, Incheon, Cheongju-si, Busan
2020-01-07
Active, closed
Role of FFR in ACS Patients: Pressure ACS Registry
NCT05896501Acute Coronary Syndrome
The Catholic University of Korea
Observational
500
Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul
2020-01-01
Active, closed
Galderma R&D
Phase 3
1,700
Bucheon-si, Busan, Gyeonggi-do, Incheon, Seoul
2019-12-30
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
Incheon, Seoul
2019-11-07
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
Goyang-si, Gyeonggi-do, Incheon, Seoul, Soeul, Suwon
2019-10-31
Active, closed
GlaxoSmithKline
Phase 1/2
208
Incheon, Seoul
2019-10-07
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Busan, Daegu, Gyeonggi-do, Incheon, Seongnam-si, Seoul, Suwon
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Seoul, Incheon
2019-09-23
Active, closed
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
DrugsParaplatin·Taxol·Letrozole·Paclitaxel
NRG Oncology
Phase 3
450
Goyang-si, Seoul, Seongnam, Daegu, Incheon
2019-09-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Daegu, Goyang-si, Incheon, Seoul
2019-09-18
Active, closed
Sanofi
Observational
1,860
Ansan-si, Suwon, Incheon, Seoul
2019-08-15
Active, closed
AstraZeneca
Phase 3
923
Busan, Cheonan-si, Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2019-06-25
Active, closed
SCM Lifescience Co., LTD.
Observational
42
Bucheon-si, Daegu, Goyang-si, Gwangju, Incheon, Suwon
2019-05-10
Active, closed
Corvus Pharmaceuticals, Inc.
Phase 1
151
Seoul, Busan, Incheon
2019-05-03
Active, closed
Eisai Inc.
Phase 3
1,906
Seongnam-si, Gwangju, Busan, Incheon, Seoul
2019-03-27
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
Cheongju-si, Daejeon, Goyang, Incheon, Seoul
2019-03-22
Active, closed
Acerta Pharma BV
Phase 3
984
Incheon, Seoul
2019-02-25
Active, closed
AbbVie
Phase 1
364
Incheon, Hwasun-gun, Seoul
2019-02-21
Active, closed
Travere Therapeutics, Inc.
Phase 3
406
Seongnam-si, Anyang-si, Busan, Incheon, Seoul
2018-12-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Seoul, Wŏnju, Bundang Gu, Suwon, Gyeonggi-do, Cheongju-si, Incheon, Seongnam Gyeonggi
2018-12-07
Active, closed
OBI Pharma, Inc
Phase 3
575
Busan, Goyang-si, Incheon, Seongnam-si, Seoul, Suwon
2018-12-05
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Daegu, Goyang-si, Gyeonggi-do, Incheon, Jeollanam-do, Jeonju, Seongnam-si, Seoul
2018-11-28
Recruiting
IRIS- DESyne X2 in the IRIS-DES Registry
NCT03588481Coronary Stenosis, Coronary Occlusion, Coronary Disease
Seung-Jung Park
Observational
1,000
Incheon, Seoul, Suncheon
2018-11-28
Active, closed
Safety and Efficacy of the ANTHEM™ CR Total Knee System
NCT03885622Non-inflammatory Degenerative Joint Disease
Smith & Nephew Pte Ltd
Observational
153
Hwasun, Incheon
2018-11-23
Active, closed
AstraZeneca
Phase 3
1,063
Daegu, Goyang-si, Gyeonggi-do, Incheon, Seoul
2018-11-16
Active, closed
AbbVie
Phase 3
265
Incheon, Seoul, Ulsan
2018-10-22
Active, closed
AbbVie
Phase 2
270
Goyang-si, Seongnam, Suwon, Yangsan, Incheon, Hwasun-gun, Cheongju-si, Seoul
2018-10-10
Active, closed
AstraZeneca
Phase 3
1,246
Goyang-si, Incheon, Seoul, Suwon
2018-09-27
Active, closed
Hoffmann-La Roche
Phase 3
257
Gyeonggi-do, Incheon, Jeollanam-do, Seoul
2018-08-16
Active, closed
AstraZeneca
Phase 3
216
Cheongju-si, Incheon, Seongnam-si, Seoul
2018-07-19
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Seongnam-si, Suwon, Seoul, Incheon
2018-06-21
Active, closed
Exelixis
Phase 3
837
Goyang-si, Suwon, Busan, Incheon, Seoul
2018-06-10
Active, closed
pharmaand GmbH
Phase 3
1,097
Goyang-si, Seongnam-si, Incheon, Cheonan, Seoul, Suwon
2018-05-14
Active, closed
MedImmune LLC
Phase 1
400
Cheongju-si, Gyeonggi-do, Incheon, Seoul
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Busan, Daejeon, Goyang-si, Gwangju, Gyeonggi-do, Incheon, Seoul, Wŏnju
2018-03-23
Active, closed
AstraZeneca
Phase 2
154
Incheon, Seoul
2018-03-16
Active, closed
AstraZeneca
Phase 2
273
Cheongju-si, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2018-03-07
Active, closed
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms
DrugsSavolitinib·Sunitinib
AstraZeneca
Phase 3
60
Daejeon, Goyang-si, Hwasun-gun, Incheon, Seoul
2017-07-25
Active, closed
Eli Lilly and Company
Phase 3
5,637
Cheongju-si, Cheonan-si, Incheon, Namdong-gu, Goyang-si, Seongnam, Busan, Haeundae-gu
2017-07-12
Active, closed
AstraZeneca
Phase 3
1,186
Busan, Chungcheongbuk-do, Daegu, Incheon, Seongnam-si, Seoul, Ulsan
2017-06-01
Active, closed
AstraZeneca
Phase 3
987
Changwon, Cheongju-si, Daegu, Incheon, Jinju, Seongnam-si, Seoul
2017-03-27
Active, closed
Acerta Pharma BV
Phase 3
310
Busan, Daegu, Gyeonggi-do, Incheon, Jeonju, Seoul, Tonggu
2017-02-02
Active, closed
AstraZeneca
Phase 3
669
Changwon-si, Cheongju-si, Daegu, Incheon, Jinju, Seoul, Suwon
2017-01-02
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Busan, Daegu, Goyang-si, Hwasun-gun, Incheon, Seongnam-si, Seoul, Suwon
2016-09-13
Recruiting
Seung-Jung Park
Observational
4,000
Seoul, Busan, Cheonan, Daegu, Daejeon, Ilsan, Incheon, Jeju City
2016-07
Recruiting
Samsung Medical Center
Observational
797
Incheon, Seongnam, Seoul, Taebuk, Ulsan
2016-06-10
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Cheongju-si, Goyang-si, Incheon, Seongnam-si, Seoul
2016-05-24
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Dalseo-gu, Seongnam, Incheon, Seoul
2016-05-03
Recruiting
Boston Scientific Corporation
Observational
300
Incheon
2016-03-07
Active, closed
Geron Corporation
Phase 2/3
289
Seogu, Incheon, Hwasun, Seoul
2016-01-12
Active, closed
AstraZeneca
Phase 3
1,126
Incheon, Seongnam-si, Seoul
2015-11-02
Active, closed
AstraZeneca
Phase 3
1,118
Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Incheon, Jinju
2015-07-21
Active, closed
Janssen Research & Development, LLC
Phase 2
239
Daejeon, Goyang-si, Incheon, Seoul
2015-04-22
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Seongnam-si, Yangsan, Hwasun-gun, Incheon, Seoul
2014-12-17
Active, closed
Eli Lilly and Company
Phase 3
493
Incheon, Goyang-si, Seongnam, Seoul, Daegu, Ulsan
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
Goyang-si, Incheon, Seoul, Seowon-Gu, Suwon, Ulsan
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Active, closed
Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population
NCT02112214Gastric Cancer, Helicobacter Pylori Infection
National Cancer Center, Korea
Phase 3
5,224
Busan, Chuncheon, Daegu, Goyang, Gwangju, Incheon, Seoul, Uijeongbu-si
2014-06
Active, closed
AstraZeneca
Phase 3
1,837
Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2014-04-22
Active, closed
Genentech, Inc.
Phase 2
378
Daegu, Gyeonggi-do, Incheon, Seoul
2008-10-16
Active, closed
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
DrugsHD204·Bevacizumab-awwb·BP102·Zirabev
National Cancer Institute (NCI)
Phase 3
1,052
Dalseo-gu, Goyang-si, Seoul, Seongnam, Incheon, Suwon
2007-12-06
Rows per page Showing 1–351 of 351
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/incheon

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 351 of those studies with a site in Incheon.

How many clinical trials are recruiting in Incheon?

161 of the 351 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 11 have not yet opened recruitment, 173 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Incheon), 351 studies
PhaseStudiesRecruitingShare
Phase 31897553.8%
Phase 2612717.4%
Observational27207.7%
Not applicable26177.4%
Phase 1/21774.8%
Phase 11133.1%
Phase 41183.1%
Phase 2/3942.6%

Most active sponsors

Lead sponsors with the most studies (Incheon)
Lead sponsorStudiesRecruiting
AstraZeneca3614
Eli Lilly and Company156
Hoffmann-La Roche144
Novartis Pharmaceuticals138
GlaxoSmithKline112
Janssen Research & Development, LLC111
Regeneron Pharmaceuticals115
Boehringer Ingelheim86
Amgen72
Inha University Hospital74
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.